In vitro biosynthesis, isolation, and identification of predominant metabolites of 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one (RVX-208)

The two main metabolites (M4 and M5) of the clinical candidate RVX-208 were produced via biosynthesis, identified using LC-MS/MS and NMR, and the structures were confirmed via chemical synthesis.